Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study to Investigate ANS014004 in Participants With Locally Advanced or Metastatic Solid Tumors
Sponsor: Avistone Biotechnology Co., Ltd.
Summary
This is a Phase 1, first-in-human, open-label, multi-center study with the aim of exploring the safety, tolerability, PK, and preliminary anti-tumor activity of ANS014004 as a single agent in participants with locally advanced or metastatic solid tumors.
Official title: A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ANS014004 as a Single Agent in Participants With Locally Advanced or Metastatic Solid Tumors
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
63
Start Date
2024-06-24
Completion Date
2027-10
Last Updated
2026-03-13
Healthy Volunteers
No
Interventions
ANS014004
Varying doses of ANS014004
Locations (10)
University of California, San Diego
San Diego, California, United States
Sarah Cannon Research Institute
Denver, Colorado, United States
Advent Health
Orlando, Florida, United States
Henry Ford Health Cancer
Detroit, Michigan, United States
NYU Langone Health
New York, New York, United States
The University of Texas - MD Anderson Cancer Center
Houston, Texas, United States
NEXT Oncology, Virginia
Fairfax, Virginia, United States
Swedish Cancer Institute
Seattle, Washington, United States
BC Cancer Vancouver Centre
Vancouver, British Columbia, Canada
Princess Margaret Cancer Centre
Toronto, Ontario, Canada